CD44在恶性胸水中的表达及其与肺癌预后相关性的分析  

Expression of CD44 in Pleural Effusion Cells and the Relationship of Prognosis in Human Lung Cancer

作　　者：华云旗[1] 尹芳蕊[2] 毋永娟[1] 杨永岩[1] 王晓君[1] 王芳[2] 

机构地区：[1]包头市肿瘤医院肿瘤内科一病区,内蒙古包头014030 [2]包头医学院第一附属医院中心实验室,内蒙古包头014030

出　　处：《内蒙古医学杂志》2012年第9期1030-1032,F0003,共4页Inner Mongolia Medical Journal

摘　　要：目的：观察恶性胸水脱落细胞中CD44的表达情况,初步分析CD44表达与肺癌胸腔转移预后的相关性。方法：2006~2008年就诊我院52例恶性胸水患者,HE染色法检测胸水脱落细胞中恶性细胞,免疫组织化学法检测恶性胸水脱落细胞CD44表达情况,经统计分析不同病理类型脱落细胞CD44表达差异,观察CD44＋和CD44-患者接受TP/GP方案后的临床疗效;比较两组临床疗效和生存期差异。结果：52例肺癌胸腔转移患者中CD44阳性率59.6%（31/52）;其中腺癌阳性率为55.0%（22/40）,鳞癌阳性率为75.0%（9/12）,阳性率比较差异有统计学意义（P〈0.05）。应用标准方案化疗后CD44＋组和CD44-组临床有效率分别为：22.7%（5/21）和19.4%（6/31）,两组比较P〈0.05,差异有统计学意义,生存期分析显示：CD44-组明显长于CD44＋组。结论：肺癌胸腔转移患者中鳞癌CD44阳性率高于腺癌,且CD44＋患者在标准方案化疗下临床疗效差,患者预后较差。因此,CD44可以作为肺癌胸腔转移患者不良预后因子之一,值得临床进一步深入研究。Objective：The aim of this study is to observe the expression of CD44 in malignant pleural effusion and analysis the relationship of prognosis between CD44 expression and pleural metastases in lung cancer preliminarily.Methods：From 2006 to 2008,52 patients with malignant pleural effusion were studied.Haematoxylin eosin（HE） staining was used for histological evaluation in malignant pleural effusion.The expression of CD44 in malignant pleural effusion was determined by immunohistochemistry.The survival analysis was obtained using the Kaplan-Meier test.Results：52 cases of lung cancer in patients with pleural metastases position rate of CD44 was 59.6%（31/52）,55.0% in adenocarcinoma and 75.0% in squamous cell,comparative difference was statistically significant（P0.05）.Using standard chemotherapy regimen for CD44＋and CD44-groups,the rate of clinical efficient was 22.7%（5/21）and 19.4%（6/31）respectively.There was significant difference between two groups（P0.05）.The survival analysis shows that,CD44＋group longer than CD44-group obviously.Conclusions：Cell adhesion molecule CD44 is highly expressed in pleural effusion cells.CD44 expression is correlated with a poor prognosis in pleural metastases in lung cancer.CD44 can,therefore,be utilized as a prognostic marker for this group of patients.

关 键 词：CD44 肺癌 恶性胸腔积液 免疫组化 化疗 

分 类 号：R734.2[医药卫生—肿瘤]